Determine the Existence and Sequence of ARMS2 Protein

Principal Investigator
Gaofeng Wang, PhD
University of Miami Miller School of Medicine
Miami, FL, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
July 01, 2012 - June 30, 2014
Grant ID
M2012048
Co-Principal Investigator(s)
Sander Dubovy, MD, Bascom Palmer Eye Institute
Goals
The gene called ARMS2 is strongly associated with the risk of developing age-related macular degeneration (AMD). The existence and the sequence (i.e., “spelling”) of an ARMS2 protein have not yet been proven experimentally. Drs. Gaofeng Wang, Sander Dubovy, and colleagues plan to prove the existence or non-existence of ARMS2 protein in human retina tissues.
Summary
The goal of this project is to determine the existence and the sequence of the different forms of the ARMS2 protein that may be found in human retinas.
There is an ongoing debate about whether ARMS2 is a protein-coding gene. Drs. Gaofeng Wang, Sander Dubovy, and colleagues recently identified a novel ARMS2 transcript splice variant (a message sent by the gene asking the cell’s machinery to make protein), which predicts a novel ARMS2 protein isoform. These researchers enrich and collect ARMS2 protein from an in vitro translation system (making the protein in a test tube) and from donor eye tissues. The recovered, intact ARMS2 proteins are being analyzed by a special protein cataloging and sequencing technique (called a mass spectrometry-based proteomics approach).
The ARMS2 gene represents one of the two strongest genetic associations in AMD. However, it remains largely unknown how the ARMS2 gene biologically contributes to the disease. While ARMS2 transcripts have been found in human retinas, the existence of ARMS2 protein is under debate.
When this study is completed, Wang intends to have proven the existence and determined the sequences of the various forms of the ARMS2 protein. The different ARMS2 proteins could play distinct roles in the health of the retina or in the development of AMD. These results could further advance our understanding of the genetic risks associated with AMD.
Grants
Related Grants
Macular Degeneration Research
The Novel Role of an Intracellular Nuclear Receptor in AMD Pathogenesis
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Neetu Kushwah, PhD
Current Organization
Boston Children’s Hospital
The Novel Role of an Intracellular Nuclear Receptor in AMD Pathogenesis
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Neetu Kushwah, PhD
Current Organization
Boston Children’s Hospital
Macular Degeneration Research
Exploring How NRF2 Protein Reduces RPE Cell Damage by Cigarette Smoke
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Krishna Singh, PhD
Current Organization
Johns Hopkins University School of Medicine
Exploring How NRF2 Protein Reduces RPE Cell Damage by Cigarette Smoke
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Krishna Singh, PhD
Current Organization
Johns Hopkins University School of Medicine
Macular Degeneration Research
The Development of a Transplant-Independent Therapy for RPE Dysfunction
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Shintaro Shirahama, MD, PhD
Current Organization
Schepens Eye Research Institute of Massachusetts Eye and Ear
The Development of a Transplant-Independent Therapy for RPE Dysfunction
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Shintaro Shirahama, MD, PhD
Current Organization
Schepens Eye Research Institute of Massachusetts Eye and Ear